Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Reduced Infection and Mucositis In Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate.

Oreola Donini, PhD, Brynmor A Watkins, PhD, John Palardy, Steven Opal, MD, Stephen Sonis, DMD, DMSc, Michael J. Abrams, PhD, John R. North, PhD

Blood (2010) 116 (21): 3781.

https://doi.org/10.1182/blood.V116.21.3781.3781

Published: 2010

Journal Articles

Oral Mucositis (OM) and Outcomes of Allogeneic (AL) Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hematologic Malignancies.

Montserrat Vera-Llonch, MD, MPH, Gerry Oster, PhD, Colleen Ford, John Lu, PhD, Irina Khazanov, Stephen Sonis, DMD, DMSc

Blood (2005) 106 (11): 3126.

https://doi.org/10.1182/blood.V106.11.3126.3126

Published: 2005

Journal Articles

Oral Mucositis (OM) and Outcomes of Autologous (AU) Hematopoietic Stem Cell Transplantation (HSCT) Following High-Dose Melphalan (MP) Conditioning for Multiple Myeloma (MM).

Gerry Oster, PhD, Montserrat Vera-Llonch, MD, M.P.H., Colleen Ford, John Lu, MD, Irina Khazanov, Stephen Sonis, DMD, DMSc

Blood (2005) 106 (11): 1343.

https://doi.org/10.1182/blood.V106.11.1343.1343

Published: 2005

Journal Articles

Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

Corey Cutler, MD MPH FRCPC, Shuli Li, MS, Haesook T. Kim, PhD, Edwin Alyea, MD, Vincent Ho, MD, Stephanie J. Lee, MD MPH, David C. Fisher, MD, Robert Schlossman, MD, David Miklos, MD PhD, Stephen Sonis, DMD DMSc, Robert Soiffer, MD, Joseph H. Antin, MD

Blood (2004) 104 (11): 1227.

https://doi.org/10.1182/blood.V104.11.1227.1227

Published: 2004

Journal Articles

Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.

Corey Cutler, MD MPH FRCPC, Shuli Li, MS, Haesook T. Kim, PhD, Patricia Laglenne, MS RD, Colleen Ford, Vincent Ho, MD, Stephanie J. Lee, MD MPH, Edwin Alyea, MD, Robert Soiffer, MD, Joseph H. Antin, MD, Stephen Sonis, DMD DMSc

Blood (2004) 104 (11): 351.

https://doi.org/10.1182/blood.V104.11.351.351

Published: 2004

NARROW

Reduced Infection and Mucositis In Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate.

Oral Mucositis (OM) and Outcomes of Allogeneic (AL) Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hematologic Malignancies.

Oral Mucositis (OM) and Outcomes of Autologous (AU) Hematopoietic Stem Cell Transplantation (HSCT) Following High-Dose Melphalan (MP) Conditioning for Multiple Myeloma (MM).

Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.

Email alerts

ASH Publications

American Society of Hematology

Reduced Infection and Mucositis In Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate.

Oral Mucositis (OM) and Outcomes of Allogeneic (AL) Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hematologic Malignancies.

Oral Mucositis (OM) and Outcomes of Autologous (AU) Hematopoietic Stem Cell Transplantation (HSCT) Following High-Dose Melphalan (MP) Conditioning for Multiple Myeloma (MM).

Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only